Down syndrome and leukemia: An insight into the disease biology and current treatment options.

doi:10.1016/j.blre.2023.101154

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Down syndrome and leukemia: An insight into the disease biology and current treatment options.

Blood reviews - 1 Mar 2024

Barwe Sonali P, Kolb E Anders, Gopalakrishnapillai Anilkumar

Abstract excerpt

Children with Down syndrome (DS) have a 10- to 20-fold greater predisposition to develop acute leukemia compared to the general population, with a skew towards myeloid leukemia (ML-DS). While ML-DS is known to be a subtype with good outcome, patients who relapse face a dismal prognosis. Acute lymphocytic leukemia in DS (DS-ALL) is considered to have poor prognosis. The relapse rate is high in DS-ALL compared to...

Topics

Child
Animals
Humans
Down Syndrome
Leukemia, Megakaryoblastic, Acute
GATA1 Transcription Factor
Mutation
Recurrence
Biology

Source

Open in PubMed

Identifiers

PMID: 38016838
DOI: 10.1016/j.blre.2023.101154

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics